However, in order to understand whether the two treatments able to induce a significant augmented survival rate in glioma-bearing mice (i.e., CTX-CNF1 and CTX) could produce an effect also on glioma proliferation, we performed immunostaining for the Ki67 marker 24 and 48 h after systemic drug delivery. This evidence concerns the gene MKI67 and central nervous system cancer.